{"id":299,"date":"2022-05-23T12:03:03","date_gmt":"2022-05-23T10:03:03","guid":{"rendered":"\/blog\/?page_id=299"},"modified":"2025-01-02T16:24:27","modified_gmt":"2025-01-02T15:24:27","slug":"infliximab-remicade","status":"publish","type":"page","link":"\/blog\/traitements\/infliximab-remicade\/","title":{"rendered":"Infliximab (Remicade) 2008-2013"},"content":{"rendered":"\n<div class=\"wp-block-image\"><figure class=\"alignleft size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"502\" height=\"384\" src=\"\/blog\/wp-content\/uploads\/2022\/05\/remicade_packshot.jpg\" alt=\"\" class=\"wp-image-300\" srcset=\"\/blog\/wp-content\/uploads\/2022\/05\/remicade_packshot.jpg 502w, \/blog\/wp-content\/uploads\/2022\/05\/remicade_packshot-300x229.jpg 300w\" sizes=\"auto, (max-width: 502px) 100vw, 502px\" \/><\/figure><\/div>\n\n\n\n<p>L&rsquo;infliximab est un anticorps monoclonal chim\u00e9rique humain\/souris qui se lie avec une grande affinit\u00e9 \u00e0 la fois aux formes soluble et transmembranaire du TNF (<em>Tumor Necrosis Factor<\/em>)-alpha, mais pas \u00e0 la lymphotoxine&nbsp;alpha (TNF-\u00df).<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>Indications th\u00e9rapeutiques:<\/strong><br>Maladies de Crohn<br>Polyarthrites rhumato\u00efdes<br>Psoriasis en plaques<br>Rectocolites h\u00e9morragiques<br>Rhumatismes psoriasiques<br>Spondylarthrites ankylosantes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&rsquo;infliximab est un anticorps monoclonal chim\u00e9rique humain\/souris qui se lie avec une grande affinit\u00e9 \u00e0 la fois aux formes soluble et transmembranaire du TNF (Tumor<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":278,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-299","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"\/blog\/wp-json\/wp\/v2\/pages\/299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/blog\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"\/blog\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"\/blog\/wp-json\/wp\/v2\/comments?post=299"}],"version-history":[{"count":2,"href":"\/blog\/wp-json\/wp\/v2\/pages\/299\/revisions"}],"predecessor-version":[{"id":348,"href":"\/blog\/wp-json\/wp\/v2\/pages\/299\/revisions\/348"}],"up":[{"embeddable":true,"href":"\/blog\/wp-json\/wp\/v2\/pages\/278"}],"wp:attachment":[{"href":"\/blog\/wp-json\/wp\/v2\/media?parent=299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}